Terumo Blood and Cell Technologies (TBCT) welcomes the opportunity to provide feedback on the Commission’s Proposal for a Regulation on Substances of Human Origin (SoHO). While the Proposal significantly improves the regulatory framework for SoHO products, additional steps outlined in this submission will strengthen the Regulation to ensure greater protection for patients and donors, and safeguard SoHO products…
TB
Terumo BCT
Company · Belgium · EU Transparency Register 294466410821-65
2
positions filed
in the 665 files tracked
1
legislative file
of 665 tracked
0
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,800 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1212 companies & groups on this site, they rank #819 by legislative files engaged, a count of participation, not a measure of influence.
1
declared lobbying FTE
self-declared
€200K+
declared costs / yr (floor)
1
EP accreditations
as declared to the register
2013
in the register since
Declares membership of
- MedTech Europe www.medtecheurope.org/
- MedPharmPlast www.medpharmplasteurope.org/
- Blood Transfusion Association (BTA) https://bloodtransfusionassociation.org/
- Brussels Resilience Forum
Self-declared to the EU Transparency Register (snapshot 15 Oct 2026).
- Register category
- Companies & groups
- Registered as
- Terumo Blood and Cell Technologies
- Head office
- Zaventem, Belgium
Self-declared to the EU Transparency Register (snapshot 15 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Terumo in PolicySpeak: request access →
Work at Terumo BCT? so we know who speaks for it.
Their record over time
Terumo BCT filed 2 positions between 14 Dec 2020 and 7 Sept 2022, across 1 of the 665 legislative files tracked here.
2020 · 1 filed2022 · 1 filed
What they argued
Terumo BCT welcomes the European Commission’s Inception Impact Assessment (IIA) on the revision of the blood, tissues and cells (BTC) legislation. Terumo BCT is a global leader in blood component, therapeutic apheresis and cellular technologies. As rightly pointed out in the IIA, the BCT legislation lags behind innovation.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Terumo BCT next to another organization. Same files, same register facts, side by side. Compare →
Is this your organization?
Everything on this page comes from Terumo BCT’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.